{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-001196","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2026-09-09T13:01:06+00:00","discovered_at":"2026-09-09T13:02:03.385425+00:00","generated_at":"2026-09-09T13:02:10.631319+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Immunic holds RMS R&D Day webinar; presentation details not in filing","bullets":["Immunic hosted RMS R&D Day webinar Sept 9, 2026, 11:00-12:30 ET via video conference.","Presentation content not included in filing text; no specific clinical data or milestones disclosed in body.","Forward-looking statements cite vidofludimus calcium and potential confirmatory phase 3 trial in progressive MS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-001196","json":"https://secwatch.observer/filing/0001193805-26-001196.json","markdown":"https://secwatch.observer/filing/0001193805-26-001196.md","text":"https://secwatch.observer/filing/0001193805-26-001196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526001196/0001193805-26-001196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526001196/e665768_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T13:02:10.631319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}